Patents Assigned to Integragen
-
Patent number: 10400284Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.Type: GrantFiled: November 23, 2012Date of Patent: September 3, 2019Assignees: INTEGRAGEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTESInventors: Thomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud
-
Publication number: 20170298442Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of hsa-miR-31-5p (SEQ ID NO:2) miRNA in a sample of said patient. The invention also relates to kits for measuring the expression of hsa-miR-31-5p and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.Type: ApplicationFiled: September 25, 2015Publication date: October 19, 2017Applicant: IntegragenInventor: Raphaele Thiebaut
-
Publication number: 20160376661Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of at least one target gene of hsa-miR-31-3p (SEQ ID NO:1) miRNA in a sample of said patient, wherein said target gene of hsa-miR-31-3p is selected from DBNDD2 and EPB41 L4B. The invention also relates to kits for measuring the expression of DBNDD2 and/or EPB41 L4B and at least one other parameter positively or negatively correlated to response to EGFR inhibitors. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.Type: ApplicationFiled: November 26, 2014Publication date: December 29, 2016Applicant: IntegragenInventor: Raphaele THIEBAUT
-
Publication number: 20150232944Abstract: The present invention relates to the technical field of hepatocellular carcinoma (HCC) management, and more precisely to the prognosis of HCC aggressiveness and associated therapeutic decisions. The invention provides a new prognosis method of HCC aggressiveness, based on determination in vitro and analysis of an expression profile comprising genes TAF9, RAMP3, HN1, KRT19, and RAN. The invention also provides kits for the prognosis of HCC aggressiveness, and methods of treatment of HCC in a subject based on a preliminary prognosis of said subject HCC aggressiveness.Type: ApplicationFiled: September 23, 2013Publication date: August 20, 2015Applicant: IntegragenInventors: Aurelien De Reynies, Pierre Laurent-Puig, Jessica Zucman-Rossi, Jean-Charles Nault
-
Publication number: 20140127685Abstract: The invention provides methods featuring the use of polymorphisms in the JARID2 gene to diagnosis autism.Type: ApplicationFiled: October 8, 2010Publication date: May 8, 2014Applicants: The Johns Hopkins University, The General Hospital Corporation, IntegraGen SAInventors: Aravinda Chakravarti, Dan E. Arking, Mark Daly, Jerome Carayol, Francis Rousseau
-
Publication number: 20110091899Abstract: The present invention relates to a method of detecting the presence of or predisposition to autism, or to an autism spectrum disorder, the method comprising detecting the presence of an alteration in the gene loci PITX1, ATP2B2, SLC25A12 and EN2 in a sample from said subject. More particularly, the presence of specific single nucleotide polymorphisms (SNPs) within these genes correlates to a substantially increased risk to develop autism.Type: ApplicationFiled: June 12, 2009Publication date: April 21, 2011Applicant: IntegragenInventors: Jörg Hager, Frédéric Tores, Francis Rousseau
-
Publication number: 20110086777Abstract: The present invention relates to a method for evaluating the level of risk for a subject to develop autism, or an autism spectrum disorder, which method comprises determining the number of risk alleles in autism-associated gene loci in a sample of a subject, wherein the more risk alleles are detected within said gene loci combined, the more increased is the risk of developing autism or an autism-spectrum disorder.Type: ApplicationFiled: June 12, 2009Publication date: April 14, 2011Applicant: IntegragenInventors: Jérôme Carayol, Frédéric Tores, Jörg Hager
-
Publication number: 20110027393Abstract: The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes or diabetic complications, which method comprises detecting the presence of an alteration in the EEFSEC gene locus in a biological sample of said subject.Type: ApplicationFiled: April 30, 2008Publication date: February 3, 2011Applicant: INTEGRAGENInventors: Anne Philippi, Jorg Hager, Francis Rousseau
-
Publication number: 20100240539Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB 1 gene on chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCBI gene and expression products, as well as to diagnostic tools and kits based on these mutations.Type: ApplicationFiled: March 3, 2010Publication date: September 23, 2010Applicant: IntegragenInventors: Anne Philippi, Francis Rousseau, Peter Brooks, Jörg Hager
-
Publication number: 20100203517Abstract: The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the PEBP4 gene locus in a biological sample of said subject.Type: ApplicationFiled: February 20, 2008Publication date: August 12, 2010Applicant: IntegragenInventors: Anne Philippi, Jorg Hager, Francis Rousseau
-
Publication number: 20100151462Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the SHANK2 gene locus in a biological sample of said subject.Type: ApplicationFiled: February 20, 2008Publication date: June 17, 2010Applicant: IntegragenInventors: Anne Philippi, Jorg Hager, Francis Rousseau
-
Publication number: 20090215040Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the ATP2B2 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the ATP2B2 gene and expression products, as well as to diagnostic tools and kits based on these mutations.Type: ApplicationFiled: March 23, 2006Publication date: August 27, 2009Applicant: IntegragenInventors: Anne Phillippi, Francis Rousseau, Elke Roschmann
-
Publication number: 20090011414Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.Type: ApplicationFiled: February 16, 2006Publication date: January 8, 2009Applicant: IntegragenInventors: Anne Philippi, Francis Rousseau, Elke Roschmann
-
Publication number: 20080213765Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the SLC6A1 or SLC6A11 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the SLC6A1 or SLC6A11 gene and expression products, as well as to diagnostic tools and kits based on these mutations.Type: ApplicationFiled: February 27, 2006Publication date: September 4, 2008Applicant: IntegragenInventors: Anne Philippi, Francis Rousseau, Elke Roschmann
-
Publication number: 20070218057Abstract: The present invention discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MAP3K11 gene on chromosome 11 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MAP3K11 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemic hypertension.Type: ApplicationFiled: August 27, 2004Publication date: September 20, 2007Applicant: IntegragenInventors: Elke Roschmann, Francis Rousseau
-
Publication number: 20070218068Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PITX1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.Type: ApplicationFiled: June 30, 2005Publication date: September 20, 2007Applicant: INTEGRAGENInventors: Anne Philippi, Francis Rousseau, Peter Brooks, Jorg Hager
-
Publication number: 20070166714Abstract: The invention relates to methods and compositions for producing biochips as well as to the use of these biochips in diverse fields, from functional genomics to diagnosis, for example, particularly in research or in the medical field. The invention also relates to tools and methods for selecting polynucleotides that permit the production of improved biochips. The inventive biochips contain, in particular, BAC clones.Type: ApplicationFiled: June 18, 2004Publication date: July 19, 2007Applicant: INTEGRAGENInventors: Pierre Lindenbaum, Philippe Gesnouin
-
Publication number: 20070154935Abstract: The present invention discloses the identification of a human obesity susceptibility gene; which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PPYR1 gene on chromosome 10 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PPYRI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemic hypertension.Type: ApplicationFiled: February 19, 2007Publication date: July 5, 2007Applicant: INTEGRAGENInventors: Peter Brooks, Elke Roschmann, Anne Philippi, Jorg Hager
-
Publication number: 20070134664Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the SLC6A7 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the SLC6A7 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.Type: ApplicationFiled: August 20, 2004Publication date: June 14, 2007Applicant: IntegragenInventors: Jorg Hager, Anne Philippi, Elke Roschmann
-
Patent number: 7166432Abstract: The present invention relates to genetic mapping of complex quantitative and qualitative traits. This invention more particularly relates to compositions and methods to identify identical DNA fragments from two different DNA sources. The methods allow the amplification of the DNAs, their labelling, and the separation of perfectly matched DNAs from imperfectly matched DNAs or from DNAs formed through hybridization from the same source (e.g., homohybrids). The invention may be used to identify genes or gene mutations, which are relevant to pathological conditions or particular traits.Type: GrantFiled: September 5, 2003Date of Patent: January 23, 2007Assignee: IntegragenInventors: Jörg Hager, Peter Brooks